Ann Oncol 2017; 28: 1339–1345 (doi: 10.1093/annonc/mdx075)
In the original article, Figure 2B incorrectly described the curves as PFS, while it should have read OS. This has now been corrected.
. 2018 Jan 29;29(11):2269. doi: 10.1093/annonc/mdx807
Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
J J Knox
, C H Barrios
, T M Kim
, T Cosgriff
, V Srimuninnimit
, K Pittman
, R Sabbatini
, S Y Rha
, T W Flaig
, R D Page
, J T Beck
, F Cheung
, S Yadav
, P Patel
, L Geoffrois
, J Niolat
, N Berkowitz
, M Marker
, D Chen
, R J Motzer
J J Knox
Find articles by J J Knox
C H Barrios
Find articles by C H Barrios
T M Kim
Find articles by T M Kim
T Cosgriff
Find articles by T Cosgriff
V Srimuninnimit
Find articles by V Srimuninnimit
K Pittman
Find articles by K Pittman
R Sabbatini
Find articles by R Sabbatini
S Y Rha
Find articles by S Y Rha
T W Flaig
Find articles by T W Flaig
R D Page
Find articles by R D Page
J T Beck
Find articles by J T Beck
F Cheung
Find articles by F Cheung
S Yadav
Find articles by S Yadav
P Patel
Find articles by P Patel
L Geoffrois
Find articles by L Geoffrois
J Niolat
Find articles by J Niolat
N Berkowitz
Find articles by N Berkowitz
M Marker
Find articles by M Marker
D Chen
Find articles by D Chen
R J Motzer
Find articles by R J Motzer
Issue date 2018 Nov.
© The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
PMCID: PMC6290878 PMID: 29390043
This corrects the article "Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC" in volume 28 on page 1339.